KANGSTEM BIOTECH CO., LTD. Logo

KANGSTEM BIOTECH CO., LTD.

Develops stem cell therapies for rare diseases; offers culture media, cell platforms, and CDMO services.

217730 | KO

Overview

Corporate Details

ISIN(s):
KR7217730001
LEI:
Country:
South Korea
Address:
서울특별시 강남구 테헤란로 522 홍우빌딩 9층, 강남구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kangstem Biotech Co., Ltd. is a biopharmaceutical company dedicated to the research and development of stem cell therapeutics for rare and incurable diseases. The company's core mission is to address unmet medical needs through innovative, next-generation biopharmaceuticals. In addition to its therapeutic pipeline, Kangstem Biotech operates several key business segments. These include the production and commercialization of specialized stem cell culture media and mediums, noted for their efficacy in mesenchymal stem cell proliferation. The company also provides a proprietary cell freezing and thawing platform and offers Contract Development and Manufacturing Organization (CDMO) services, leveraging its expertise in cell-based technologies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-01 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 159.6 KB
2025-08-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-08-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-08-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-08-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.9 KB
2025-08-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-08-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-08-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-08-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-08-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.9 KB
2025-08-28 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.1 KB
2025-08-26 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 85.3 KB
2025-08-26 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.2 KB
2025-08-25 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 7.8 KB
2025-08-25 00:00
Share Issue/Capital Change
증권발행실적보고서
Korean 158.0 KB

Automate Your Workflow. Get a real-time feed of all KANGSTEM BIOTECH CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KANGSTEM BIOTECH CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KANGSTEM BIOTECH CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden
ELIC
ELI LILLY & Co Logo
Pharma leader developing medicines for diabetes, obesity, oncology, and neuroscience.
United States of America
LLY
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden
ELN
ELUTIA INC. Logo
Develops drug-eluting biologics to reduce complications from medical implants.
United States of America
ELUT
Emergent BioSolutions Inc. Logo
Develops and manufactures medical countermeasures for public health and national security threats.
United States of America
EBS
ENANTA PHARMACEUTICALS INC Logo
Developing novel small molecule drugs for virology (HCV, RSV) and immunological diseases.
United States of America
ENTA
enGene Holdings Inc. Logo
Developing non-viral, locally administered gene therapies for rare genetic conditions.
United States of America
ENGN
Enliven Therapeutics, Inc. Logo
A clinical-stage biopharma developing kinase inhibitors for precision oncology cancer treatment.
United States of America
ELVN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy that reprograms macrophages to treat immune hyper-responses like sepsis.
United States of America
ENLV
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel
ENLV

Talk to a Data Expert

Have a question? We'll get back to you promptly.